48 related articles for article (PubMed ID: 20947393)
1. Expression of HER-2 and nuclear localization of HER-3 protein in canine mammary tumors: histopathological and immunohistochemical study.
Kim JH; Im KS; Kim NH; Yhee JY; Nho WG; Sur JH
Vet J; 2011 Sep; 189(3):318-22. PubMed ID: 20947393
[TBL] [Abstract][Full Text] [Related]
2. Expression of inflammation-mediated cluster of genes as a new marker of canine mammary malignancy.
Pawłowski KM; Homa A; Bulkowska M; Majchrzak K; Motyl T; Król M
Vet Res Commun; 2013 Jun; 37(2):123-31. PubMed ID: 23435839
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 mRNA and protein expression in canine mammary carcinomas: Correlation with histopathological grade and molecular markers.
Bae MK; Ko YU; Seung BJ; Sur JH; Choe NH
Vet Pathol; 2024 May; 61(3):402-409. PubMed ID: 38281145
[TBL] [Abstract][Full Text] [Related]
4. Inner nuclear membrane localization of epidermal growth factor receptor (EGFR) in spontaneous canine model of invasive micropapillary carcinoma of the mammary gland.
Rodrigues MA; Gamba CO; Faria JA; Ferreira Ê; Goes AM; Gomes DA; Cassali GD
Pathol Res Pract; 2016 Apr; 212(4):340-4. PubMed ID: 26944829
[TBL] [Abstract][Full Text] [Related]
5. Clinical staging in bitches with mammary tumors: Influence of type and histological grade.
Gundim LF; de Araújo CP; Blanca WT; Guimarães EC; Medeiros AA
Can J Vet Res; 2016 Oct; 80(4):318-322. PubMed ID: 27733787
[TBL] [Abstract][Full Text] [Related]
6. A Preliminary Evaluation of the Prognostic Role of HER-2 and HER-3 Immunohistochemical Expression in Canine Melanomas.
Parisi F; Aurisicchio L; Pecorari A; Poli A; Millanta F
Animals (Basel); 2024 May; 14(10):. PubMed ID: 38791617
[TBL] [Abstract][Full Text] [Related]
7. Hormone, Targeted, and Combinational Therapies for Breast Cancers: From Humans to Dogs.
Ke CH; Lin CN; Lin CS
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255807
[TBL] [Abstract][Full Text] [Related]
8. Anti-cancer effect of palmatine through inhibition of the PI3K/AKT pathway in canine mammary gland tumor CMT-U27 cells.
Yoo MJ; Choi J; Jang YJ; Park SY; Seol JW
BMC Vet Res; 2023 Oct; 19(1):223. PubMed ID: 37880653
[TBL] [Abstract][Full Text] [Related]
9. The Analysis of E-Cadherin, N-Cadherin, Vimentin, HER-2, CEA, CA15-3 and SF Expression in the Diagnosis of Canine Mammary Tumors.
Yu C; Zheng H; Liu X; Xie G
Animals (Basel); 2022 Nov; 12(21):. PubMed ID: 36359174
[TBL] [Abstract][Full Text] [Related]
10. HER2 Overexpression and Cytogenetical Patterns in Canine Mammary Carcinomas.
Muscatello LV; Gobbo F; Di Oto E; Sarli G; De Maria R; De Leo A; Tallini G; Brunetti B
Vet Sci; 2022 Oct; 9(11):. PubMed ID: 36356060
[TBL] [Abstract][Full Text] [Related]
11. Cross-species oncogenic signatures of breast cancer in canine mammary tumors.
Kim TM; Yang IS; Seung BJ; Lee S; Kim D; Ha YJ; Seo MK; Kim KK; Kim HS; Cheong JH; Sur JH; Nam H; Kim S
Nat Commun; 2020 Jul; 11(1):3616. PubMed ID: 32680987
[TBL] [Abstract][Full Text] [Related]
12. Quantitative analysis of HER2 mRNA expression by RNA in situ hybridization in canine mammary gland tumors: Comparison with immunohistochemistry analysis.
Seung BJ; Cho SH; Kim SH; Lim HY; Sur JH
PLoS One; 2020; 15(2):e0229031. PubMed ID: 32059046
[TBL] [Abstract][Full Text] [Related]
13. Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas.
Veloso ES; Gonçalves INN; Silveira TL; Oliveira FS; Vieira DS; Cassali GD; Del Puerto HL; Ferreira E
BMC Vet Res; 2020 Jan; 16(1):24. PubMed ID: 31996230
[TBL] [Abstract][Full Text] [Related]
14. Quantification of EGFR family in canine mammary ductal carcinomas in situ: implications on the histological graduation.
Veloso ES; Gonçalves INN; Arantes JA; de Abreu RVS; Cassali GD; Ferreira E
Vet Res Commun; 2019 May; 43(2):123-129. PubMed ID: 31020460
[TBL] [Abstract][Full Text] [Related]
15. Current biomarkers of canine mammary tumors.
Kaszak I; Ruszczak A; Kanafa S; Kacprzak K; Król M; Jurka P
Acta Vet Scand; 2018 Oct; 60(1):66. PubMed ID: 30373614
[TBL] [Abstract][Full Text] [Related]
16. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
17. Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors.
Nguyen F; Peña L; Ibisch C; Loussouarn D; Gama A; Rieder N; Belousov A; Campone M; Abadie J
Breast Cancer Res Treat; 2018 Feb; 167(3):635-648. PubMed ID: 29086231
[TBL] [Abstract][Full Text] [Related]
18. ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1).
Hayes DA; Kunde DA; Taylor RL; Pyecroft SB; Sohal SS; Snow ET
PLoS One; 2017; 12(6):e0177919. PubMed ID: 28591206
[TBL] [Abstract][Full Text] [Related]
19. Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccine.
Fazekas J; Fürdös I; Singer J; Jensen-Jarolim E
Oncol Lett; 2016 Oct; 12(4):2271-2276. PubMed ID: 27698788
[TBL] [Abstract][Full Text] [Related]
20. High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression.
Timmermans-Sprang EP; Gracanin A; Mol JA
BMC Cancer; 2015 Jul; 15():545. PubMed ID: 26205886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
